

Supplemental Data Table S1.

Table 1 Baseline demographics of study populations				
	Healthy group	repaglinide	metformin	rosiglitazone
n	36	35	22	25
Age(years)	52.23±8.31	51.66±7.53	51.27±7.27	48.64±7.39
Sex(M/F)	20/16	19/16	11/12	14/11

Supplemental Data Table S2.

Table 2 The parameters of OPLSDA model				
	Components	R2X(cum) ^a	R2Y(cum) ^b	Q2(cum) ^c
H vs DM0	1+4	0.357	0.769	0.496
rosiglitazone treatment 24 week post-dose vs. predose group	1+1	0.273	0.639	0.389
rosiglitazone treatment 48 week post-dose vs. predose group	1+1	0.248	0.657	0.296

^aR2X (cum) and ^bR2Y (cum) represent the cumulative Sum of Squares (SS) of all the X's and Y's explained by all extracted components,

^cQ2Y (cum) is an estimate of how well the model predicts the Y's.

Supplemental Data Figure. Validation model of 1000 random permutations. Y-axis intercepts : $R^2=(0.0, 0.144)$, $Q^2=(0.0, -0.0911)$.

